Monday, June 15, 2026

#cell therapy

4 articles

Gilead-Backed Lakefront Closes Ouro Medicines Deal, Keeps $500M for Further Autoimmune Acquisitions

Gilead-Backed Lakefront Closes Ouro Medicines Deal, Keeps $500M for Further Autoimmune Acquisitions

Salvado•Jun 13, 2026

FDA Priority Reviews and Cell Therapy Acquisitions Signal Biotech Sector Acceleration

Healthcare & Pharma Investment

FDA Priority Reviews and Cell Therapy Acquisitions Signal Biotech Sector Acceleration

Salvado•Apr 16, 2026

Artiva Biotherapeutics faces capital shortfall risk ahead of pivotal NK cell therapy trials

Corporate Finance

Artiva Biotherapeutics faces capital shortfall risk ahead of pivotal NK cell therapy trials

ViaNews Editorial Team (Finance)•Mar 7, 2026

Biotech's Commercial Inflection: What the Gene Therapy and mRNA Pipeline Surge Means for Investors

Healthcare Finance

Biotech's Commercial Inflection: What the Gene Therapy and mRNA Pipeline Surge Means for Investors

ViaNews Editorial Team (Finance)•Feb 18, 2026